PRCT
PROCEPT BioRobotics Corporation
$20.89
+1.14
(+5.77%)
Mkt Cap
1.19B
Volume
1,207,660
52W Range
19.35-62.17
Sector
Healthcare
Beta
0.87
EPS (TTM)
-1.82
P/E Ratio
-18.29
Revenue (TTM)
322.02M
Rev Growth (5Y)
+109.1%
EPS Growth (5Y)
N/A
Company Description
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 308.05M | 224.50M | 136.19M | 75.01M | 34.47M | 7.72M | 6.17M |
| Net Income | (95.57M) | (91.41M) | (105.90M) | (87.15M) | (59.85M) | (53.02M) | (41.98M) |
| EPS | -1.72 | -1.75 | -2.24 | -1.96 | -1.37 | -1.51 | -1.25 |
| Free Cash Flow | (58.34M) | (103.62M) | (133.21M) | (83.03M) | (57.93M) | (48.58M) | (51.43M) |
| FCF / Share | -1.05 | -1.99 | -2.82 | -1.87 | -1.33 | -1.38 | -1.53 |
| Operating CF | (48.98M) | (99.21M) | (108.00M) | (80.38M) | (57.33M) | (48.34M) | (43.82M) |
| Total Assets | 508.08M | 534.02M | 404.72M | 309.33M | 337.02M | 125.97M | 61.99M |
| Total Debt | 51.62M | 80.25M | 79.20M | 77.32M | 54.10M | 54.76M | 23.22M |
| Cash & Equiv | 286.50M | 333.73M | 257.22M | 222.64M | 304.32M | 100.13M | 42.02M |
| Book Value | 365.87M | 402.22M | 280.75M | 197.07M | 267.09M | 60.96M | 29.23M |
| Return on Equity | -0.26 | -0.23 | -0.38 | -0.44 | -0.22 | -0.87 | -1.44 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 83.13M | 76.38M | 83.33M | 79.18M | 69.16M | 68.24M | 58.37M | 53.35M | 44.54M | 43.58M | 35.10M | 33.10M |
| Net Income | (31.64M) | (29.84M) | (21.41M) | (19.58M) | (24.74M) | (18.86M) | (20.97M) | (25.63M) | (25.96M) | (27.50M) | (24.62M) | (25.29M) |
| EPS | -0.56 | -0.53 | -0.38 | -0.35 | -0.45 | -0.35 | -0.40 | -0.50 | -0.51 | -0.54 | -0.51 | -0.56 |
| Free Cash Flow | (41.04M) | (12.18M) | (9.50M) | (17.84M) | (18.82M) | (33.56M) | (19.05M) | (16.78M) | (34.23M) | (33.51M) | (24.72M) | (33.71M) |
| FCF / Share | -0.73 | -0.22 | -0.17 | -0.32 | -0.34 | -0.62 | -0.37 | -0.33 | -0.67 | -0.66 | -0.51 | -0.75 |
| Operating CF | (38.13M) | (10.33M) | (6.63M) | (15.04M) | (16.98M) | (32.39M) | (18.80M) | (15.74M) | (32.29M) | (24.79M) | (18.94M) | (28.34M) |
| Total Assets | 487.06M | 508.08M | 511.54M | 513.05M | 519.38M | 534.02M | 374.14M | 374.35M | 382.90M | 404.72M | 421.12M | 272.45M |
| Total Debt | 51.66M | 51.62M | 78.93M | 79.37M | 79.81M | 80.25M | 80.64M | 81.02M | 81.39M | 79.20M | 79.74M | 80.76M |
| Cash & Equiv | 245.64M | 286.50M | 294.28M | 302.72M | 316.21M | 333.73M | 196.76M | 214.09M | 225.58M | 257.22M | 287.86M | 150.47M |
| Book Value | 347.67M | 365.87M | 380.28M | 385.80M | 389.16M | 402.22M | 241.22M | 251.78M | 264.05M | 280.75M | 299.36M | 155.90M |
| Return on Equity | -0.09 | -0.08 | -0.06 | -0.05 | -0.06 | -0.05 | -0.09 | -0.10 | -0.10 | -0.10 | -0.08 | -0.16 |
PRCT News
Here Are Thursday’s Best Wall Street Analyst Research Calls: Callaway Golf, Chewy, CME Group, Danaher, General Dynamics, Intel, SpaceX, Rocket Lab, Toast, and More
PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval
AUA Guidelines Strengthen Recommendation for Aquablation® Therapy
PROCEPT BioRobotics Corporation (PRCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
PROCEPT BioRobotics® to Attend Three Upcoming Investor Conferences in May & June
PROCEPT BioRobotics Corporation (PRCT) Q1 2026 Earnings Call Transcript
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
PROCEPT BioRobotics Reports First Quarter 2026 Financial Results
Chicago Capital Doubles Down on PROCEPT BioRobotics, Adds $27 Million in Stock
Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm